Champions Oncology Stock Market Value
| CSBR Stock | USD 10.26 0.68 7.10% |
| Symbol | Champions |
Champions Oncology Price To Book Ratio
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Champions Oncology. If investors know Champions will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Champions Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.29) | Earnings Share (0.05) | Revenue Per Share | Quarterly Revenue Growth 0.166 | Return On Assets |
The market value of Champions Oncology is measured differently than its book value, which is the value of Champions that is recorded on the company's balance sheet. Investors also form their own opinion of Champions Oncology's value that differs from its market value or its book value, called intrinsic value, which is Champions Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Champions Oncology's market value can be influenced by many factors that don't directly affect Champions Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Champions Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Champions Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Champions Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Champions Oncology 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Champions Oncology's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Champions Oncology.
| 11/28/2024 |
| 02/26/2025 |
If you would invest 0.00 in Champions Oncology on November 28, 2024 and sell it all today you would earn a total of 0.00 from holding Champions Oncology or generate 0.0% return on investment in Champions Oncology over 90 days. Champions Oncology is related to or competes with Molecular Partners, MediciNova, Anebulo Pharmaceuticals, Shattuck Labs, Century Therapeutics, Aerovate Therapeutics, and Adagene. Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of ... More
Champions Oncology Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Champions Oncology's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Champions Oncology upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 5.14 | |||
| Information Ratio | 0.2127 | |||
| Maximum Drawdown | 31.59 | |||
| Value At Risk | (8.13) | |||
| Potential Upside | 10.88 |
Champions Oncology Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Champions Oncology's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Champions Oncology's standard deviation. In reality, there are many statistical measures that can use Champions Oncology historical prices to predict the future Champions Oncology's volatility.| Risk Adjusted Performance | 0.1669 | |||
| Jensen Alpha | 1.31 | |||
| Total Risk Alpha | 1.27 | |||
| Sortino Ratio | 0.2548 | |||
| Treynor Ratio | 4.73 |
Champions Oncology Backtested Returns
Champions Oncology is relatively risky given 3 months investment horizon. Champions Oncology secures Sharpe Ratio (or Efficiency) of 0.25, which signifies that the company had a 0.25 % return per unit of standard deviation over the last 3 months. We have analyzed twenty-nine different technical indicators, which can help you to evaluate if expected returns of 1.59% are justified by taking the suggested risk. Use Champions Oncology risk adjusted performance of 0.1669, and Mean Deviation of 4.64 to evaluate company specific risk that cannot be diversified away. Champions Oncology holds a performance score of 19 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of 0.28, which signifies not very significant fluctuations relative to the market. As returns on the market increase, Champions Oncology's returns are expected to increase less than the market. However, during the bear market, the loss of holding Champions Oncology is expected to be smaller as well. Use Champions Oncology coefficient of variation, semi variance, period momentum indicator, as well as the relationship between the treynor ratio and daily balance of power , to analyze future returns on Champions Oncology.
Auto-correlation | 0.26 |
Poor predictability
Champions Oncology has poor predictability. Overlapping area represents the amount of predictability between Champions Oncology time series from 28th of November 2024 to 12th of January 2025 and 12th of January 2025 to 26th of February 2025. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Champions Oncology price movement. The serial correlation of 0.26 indicates that nearly 26.0% of current Champions Oncology price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.26 | |
| Spearman Rank Test | 0.27 | |
| Residual Average | 0.0 | |
| Price Variance | 0.44 |
Champions Oncology lagged returns against current returns
Autocorrelation, which is Champions Oncology stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Champions Oncology's stock expected returns. We can calculate the autocorrelation of Champions Oncology returns to help us make a trade decision. For example, suppose you find that Champions Oncology has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Champions Oncology regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Champions Oncology stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Champions Oncology stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Champions Oncology stock over time.
Current vs Lagged Prices |
| Timeline |
Champions Oncology Lagged Returns
When evaluating Champions Oncology's market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Champions Oncology stock have on its future price. Champions Oncology autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Champions Oncology autocorrelation shows the relationship between Champions Oncology stock current value and its past values and can show if there is a momentum factor associated with investing in Champions Oncology.
Regressed Prices |
| Timeline |
Pair Trading with Champions Oncology
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Champions Oncology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Champions Oncology will appreciate offsetting losses from the drop in the long position's value.Moving together with Champions Stock
| 0.69 | PFE | Pfizer Inc Aggressive Push | PairCorr |
Moving against Champions Stock
| 0.66 | NIO | Nio Class A Buyout Trend | PairCorr |
| 0.57 | DD | Dupont De Nemours | PairCorr |
| 0.56 | CRSP | Crispr Therapeutics | PairCorr |
| 0.56 | RIG | Transocean | PairCorr |
| 0.53 | VZ | Verizon Communications Aggressive Push | PairCorr |
The ability to find closely correlated positions to Champions Oncology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Champions Oncology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Champions Oncology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Champions Oncology to buy it.
The correlation of Champions Oncology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Champions Oncology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Champions Oncology moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Champions Oncology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Champions Stock Analysis
When running Champions Oncology's price analysis, check to measure Champions Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Champions Oncology is operating at the current time. Most of Champions Oncology's value examination focuses on studying past and present price action to predict the probability of Champions Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Champions Oncology's price. Additionally, you may evaluate how the addition of Champions Oncology to your portfolios can decrease your overall portfolio volatility.